Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2003

Open Access 01-12-2003 | Original investigation

Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.

Authors: Marek Straczkowski, Irina Kowalska, Agnieszka Nikolajuk, Stella Dzienis-Straczkowska, Malgorzata Szelachowska, Ida Kinalska

Published in: Cardiovascular Diabetology | Issue 1/2003

Login to get access

Abstract

Background

Interleukin 8 (IL-8) is a cytokine with atherogenic properties. In vitro studies revealed that it is produced and secreted by human adipocytes. We recently reported that plasma IL-8 is increased in obese subjects with normal glucose tolerance (NGT). The aim of the present study was to measure plasma IL-8 concentrations in subjects with impaired glucose tolerance (IGT).

Methods

A total of 44 subjects with marked overweight or obesity (BMI > 27.8 kg/m2), 27 with NGT and 17 with IGT, were recruited for the present study. Plasma IL-8 levels were measured in fasting state, after an oral glucose tolerance test (OGTT) and after euglycemic hyperinsulinemic clamp.

Results

The studied groups did not differ in fasting IL-8 concentrations. Both OGTT and clamp resulted in a significant increase in plasma IL-8. The change in IL-8 after clamp was similar in both groups. In contrast, after OGTT plasma IL-8 levels (IL-8OGTT) were markedly higher in IGT individuals. In IGT, but not NGT group, IL-8OGTT was positively related to postload glucose and negatively to insulin sensitivity.

Conclusion

Plasma IL-8 concentrations after glucose load are increased in obese IGT subjects in comparison to normoglycemic weight-matched individuals. Increase in plasma IL-8 might be both insulin-mediated (during clamp) and glucose-mediated (during OGTT).
Literature
1.
go back to reference Jarrett RJ: The cardiovascular risk associated with impaired glucose tolerance. Diabet Med. 1996, 13: S15-S19.PubMed Jarrett RJ: The cardiovascular risk associated with impaired glucose tolerance. Diabet Med. 1996, 13: S15-S19.PubMed
2.
go back to reference Hubert H, Feinleb M, McNamara P, Castelli W: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham study. Circulation. 1983, 67: 968-977.CrossRefPubMed Hubert H, Feinleb M, McNamara P, Castelli W: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham study. Circulation. 1983, 67: 968-977.CrossRefPubMed
3.
go back to reference Pickup JC, Crook MA: Is type 2 diabetes a disease of the innate immune system?. Diabetologia. 1998, 41: 1241-1248. 10.1007/s001250051058.CrossRefPubMed Pickup JC, Crook MA: Is type 2 diabetes a disease of the innate immune system?. Diabetologia. 1998, 41: 1241-1248. 10.1007/s001250051058.CrossRefPubMed
4.
go back to reference Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed
5.
go back to reference Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Luster AD, Luscinskas FW, Rosenzweig A: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999, 398: 718-723. 10.1038/19546.CrossRefPubMed Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Luster AD, Luscinskas FW, Rosenzweig A: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999, 398: 718-723. 10.1038/19546.CrossRefPubMed
6.
go back to reference Yue TL, Mckenna PJ, Gu JL, Feuerstein GZ: Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur J Pharmacol. 1993, 240: 81-84. 10.1016/0014-2999(93)90549-W.CrossRefPubMed Yue TL, Mckenna PJ, Gu JL, Feuerstein GZ: Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur J Pharmacol. 1993, 240: 81-84. 10.1016/0014-2999(93)90549-W.CrossRefPubMed
7.
go back to reference Liu Y, Hulten LM, Wiklund O: Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol. 1997, 17: 317-323.CrossRefPubMed Liu Y, Hulten LM, Wiklund O: Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol. 1997, 17: 317-323.CrossRefPubMed
8.
go back to reference Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation. 1999, 99: 420-426.CrossRefPubMed Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation. 1999, 99: 420-426.CrossRefPubMed
9.
go back to reference Bruun JM, Pedersen SB, Richelsen B: Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res. 2000, 32: 537-541.CrossRefPubMed Bruun JM, Pedersen SB, Richelsen B: Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res. 2000, 32: 537-541.CrossRefPubMed
10.
go back to reference Bruun JM, Pedersen SB, Richelsen B: Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001, 86: 1267-1273.PubMed Bruun JM, Pedersen SB, Richelsen B: Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001, 86: 1267-1273.PubMed
11.
go back to reference Strączkowski M, Dzienis-Strączkowska S, Stêpieñ A, Kowalska I, Szelachowska M, Kinalska I: Plasma interleukin 8 concentrations are increased in obese subjects and are related to fat mass and tumor necrosis factor-α system. J Clin Endocrinol Metab. 2002, 87: 4602-4606. 10.1210/jc.2002-020135.CrossRefPubMed Strączkowski M, Dzienis-Strączkowska S, Stêpieñ A, Kowalska I, Szelachowska M, Kinalska I: Plasma interleukin 8 concentrations are increased in obese subjects and are related to fat mass and tumor necrosis factor-α system. J Clin Endocrinol Metab. 2002, 87: 4602-4606. 10.1210/jc.2002-020135.CrossRefPubMed
12.
go back to reference Zozuliñska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B: Serum interleukin-8 level is increased in diabetic patients. Diabetologia. 1999, 42: 117-118. 10.1007/s001250051124.CrossRefPubMed Zozuliñska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B: Serum interleukin-8 level is increased in diabetic patients. Diabetologia. 1999, 42: 117-118. 10.1007/s001250051124.CrossRefPubMed
13.
go back to reference DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-E223.PubMed DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-E223.PubMed
14.
go back to reference Gonzalez C, Cava F, Ayllon A, Guevara P, Navajo JA, Gonzalez-Bultrago JM: Biological variation of interleukin-1β, interleukin-8 and tumor necrosis factor-α in serum of healthy individuals. Clin Chem Lab Med. 2001, 39: 836-841.CrossRefPubMed Gonzalez C, Cava F, Ayllon A, Guevara P, Navajo JA, Gonzalez-Bultrago JM: Biological variation of interleukin-1β, interleukin-8 and tumor necrosis factor-α in serum of healthy individuals. Clin Chem Lab Med. 2001, 39: 836-841.CrossRefPubMed
15.
go back to reference Urakaze M, Temaru R, Satou A, Yamazaki K, Hamazaki T, Kobayashi M: The IL-8 production in endothelial cells is stimulated by high glucose. Horm Metab Res. 1996, 28: 400-401.CrossRefPubMed Urakaze M, Temaru R, Satou A, Yamazaki K, Hamazaki T, Kobayashi M: The IL-8 production in endothelial cells is stimulated by high glucose. Horm Metab Res. 1996, 28: 400-401.CrossRefPubMed
16.
go back to reference Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002, 16: 1-4. 10.1002/jcla.2057.CrossRefPubMed Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002, 16: 1-4. 10.1002/jcla.2057.CrossRefPubMed
17.
go back to reference Kowalska I, Prokop J, Bachórzewska-Gajewska H, Telejko B, Kinalska I, Kochman W, Musiał W: Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as a predictor for coronary atherosclerosis. Diabetes Care. 2001, 24: 897-901.CrossRefPubMed Kowalska I, Prokop J, Bachórzewska-Gajewska H, Telejko B, Kinalska I, Kochman W, Musiał W: Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as a predictor for coronary atherosclerosis. Diabetes Care. 2001, 24: 897-901.CrossRefPubMed
Metadata
Title
Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.
Authors
Marek Straczkowski
Irina Kowalska
Agnieszka Nikolajuk
Stella Dzienis-Straczkowska
Malgorzata Szelachowska
Ida Kinalska
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2003
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-2-5

Other articles of this Issue 1/2003

Cardiovascular Diabetology 1/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.